0001181431-13-017269.txt : 20130315
0001181431-13-017269.hdr.sgml : 20130315
20130315182056
ACCESSION NUMBER: 0001181431-13-017269
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130315
FILED AS OF DATE: 20130315
DATE AS OF CHANGE: 20130315
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Robinson Cynthia Y
CENTRAL INDEX KEY: 0001307695
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34962
FILM NUMBER: 13695572
MAIL ADDRESS:
STREET 1: 3280 BAYSHORE BOULEVARD
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ZOGENIX, INC.
CENTRAL INDEX KEY: 0001375151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205300780
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12400 HIGH BLUFF DRIVE
STREET 2: SUITE 650
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 259-1165
MAIL ADDRESS:
STREET 1: 12400 HIGH BLUFF DRIVE
STREET 2: SUITE 650
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: ZOGENIX INC
DATE OF NAME CHANGE: 20060911
4
1
rrd374416.xml
ROBINSON FORM 4
X0306
4
2013-03-15
0
0001375151
ZOGENIX, INC.
ZGNX
0001307695
Robinson Cynthia Y
C/O ZOGENIX, INC.
12400 HIGH BLUFF DR., SUITE 650
SAN DIEGO
CA
92130
0
1
0
0
Chief Development Officer
Right to buy stock
1.99
2013-03-15
2013-03-15
4
A
0
125000
0
A
2023-03-15
Common Stock
125000
675000
D
Right to buy stock
1.99
2013-03-15
2013-03-15
4
A
0
50000
0
A
2023-03-15
Common Stock
50000
725000
D
The option was granted on March 15, 2013 and vests in a series of forty-eight (48) successive, equal monthly installments beginning on March 15, 2013, subject to the Reporting Person's continued employment with the Company on each vesting date.
The option was granted on March 15, 2013 and vests in a series of forty-eight (48) successive, equal monthly installments beginning on March 15, 2013, subject to the Reporting Person's continued employment with the Company on each vesting date. Further, this option does not become exercisable until the Company has implemented the Zohydro ER comprehensive safe use and compliance initiatives, as determined by the Board of Directors.
Vickie Reed, Attorney-in-fact
2013-03-15